Breakout Sessions: Preparing for New Product Introduction

10:00 AM - 11:00 AM 
Rooms 146B & 146C

Following panel 1, there will be three separate breakout sessions. Each of these will explore strategies for the introduction of new interventions to developing world markets - one focusing on drugs, one on vaccines, and one on diagnostics. Panelists with on-the-ground experience will discuss key barriers to effective product introduction and key interventions at both the global and local levels to overcome these hurdles.

Focus: Therapeutic Drugs

Panelists:

  • Moderator: Wendy Woods, Partner, Boston Consulting Group
  • Geoffroy DeCarbonnel, Principal, Global Public Sector, PRTM
  • James A. Geraghty, Senior Vice President, Genzyme Corporation
  • Bernard Pécoul, CEO, Drugs for Neglected Diseases initiative
  • Inder Singh, Executive Vice President, Drug Access Programs, Clinton Foundation Health Access Initiative (CHAI)

 


Who's Who


 

decarbonnel Geoffroy DeCarbonnel - Geoffroy DeCarbonnel is a Principal in PRTM’s Global Public Sector practice. He co-leads PRTM’s work in Global Health and Development. He is currently based in Washington, DC, and has lived and worked in Europe, Africa and Asia.

At PRTM, Geoffroy works with not-for-profit and non-governmental organizations, government and commercial clients to develop their operational strategy and the capabilities necessary to achieve their mission. In helping these organizations, his work has included evaluation of public-private partnerships, design and implementation of planning processes, and supply chain strategy development. In Global Health and Development, he has focused on challenges and opportunities in global and local supply chains to improve efficient and effective delivery of product to patients, working both with international and in-country organizations. He has worked most recently on HIV, Tuberculosis and Malaria.

Prior to PRTM, Geoffroy worked in industry where he was responsible for global supply chain and logistics, and in consulting where he worked on strategy development and operational management projects. Through these assignments, Geoffroy has lived in Europe and Africa. Geoffroy earned a BScE in Aerospace Engineering from Princeton University and an MS in Industrial Administration from Carnegie Mellon University.
   
Geraghty James A. Geraghty - James A. Geraghty joined Genzyme in 1992. He is responsible for corporate development, product acquisition and partnering transactions. He led Genzyme’s recent licensing deal with Isis Pharmaceuticals and the acquisition of SangStat Medical Corporation in 2003. He oversaw the commercialization of Cholestagel in Europe and has served as president of Genzyme Europe.

Prior to joining Genzyme, Mr. Geraghty was vice president of marketing and strategic planning for Baxter/Caremark International. He has also worked as a consultant on international health care strategy at Bain and Company.

Mr. Geraghty has a JD from Yale Law School, an MS from the University of Pennsylvania and a B.A.from Georgetown University.
   
Pecoul Bernard Pécoul - Dr. Pécoul’s has led DNDi since its founding in 2003. DNDi and its partners have built the largest and most robust R&D portfolio for three of the most neglected diseases (leishmaniasis, Human African Trypanosomiasis or sleeping sickness, and Chagas disease), launched ASAQ and ASMQ, two low-cost, non-patented antimalarial combinations, and NECT, the first new treatment against sleeping sickness in 25 years. Prior to DNDi, Bernard Pécoul was director of Médecins Sans Frontières (MSF)-Access Campaign and as such played a key role in the creation of DNDi.  Before that, he was the Executive Director of MSF-France, acted as a co-founder of Epicentre, and worked as a MSF field physician in Africa, Latin America, and Asia. Bernard Pécoul obtained his Doctorate in Medicine from the University of Clermont Ferrand in France and his Master of Public Health from Tulane University in the USA.
Singh

Inder Singh - Inder Singh is the Executive Vice President of Access Programs at the Clinton Health Access Initiative (CHAI). He oversees a group of 45 business professionals and scientists, and a portfolio of initiatives to enable greater access to medicines and diagnostics. He and his team have negotiated a series of agreements with pharmaceutical companies that lowered the price of drugs for HIV/AIDS, malaria, and tuberculosis by up to 80 percent for 74 developing country governments, the World Health Organization, and the Global Fund to Fight AIDS, Malaria and Tuberculosis, leading to over $1 billion in cost savings. An estimated 3.6 million HIV/AIDS patients and over 30 million people suffering from malaria to benefit from these agreements.

Inder’s group deploys technical and management capabilities to strengthen health systems, and utilizes a market-based approach to lower prices, enhance quality, or accelerate the entry of new improved medical products. For example, by working with suppliers to reduce their costs of production, commercial risks, or the investment required to develop a product, pharmaceutical companies are willing to commit to lower prices or more rapid product development.

During the course of his work at CHAI, Inder has traveled to more than 25 countries, and has advised eight governments. Prior to joining CHAI, Inder worked in consulting and at a series of startup companies in the information technology and medical industries. Inder is also the founder of a successful nonprofit organization that supports children undergoing extensive physical rehabilitation.

Inder is a magna cum laude graduate of the University of Michigan School of Engineering and holds three graduate degrees in business administration, public policy and biomedical enterprise from MIT’s Sloan School of Management, Harvard’s Kennedy School of Government, and the Harvard-MIT Division of Health Science and Technology. He is a third degree black belt in the martial arts, enjoys scuba diving, playing strategy games especially chess and poker, and dancing.

   
Woods Wendy Woods - Wendy Woods is a Partner and Managing Director of the Boston Consulting Group.  She leads BCG’s work in global public health, and also works with bio-pharmaceutical clients.   She is currently based in BCG’s Boston office, and has worked across Europe, Asia and Africa. 

In leading BCG’s global public health efforts, Wendy works with foundations, public private partnerships and multilateral organizations.  With these organizations, she has helped to develop strategies, create public private partnerships, improve their operational effectiveness and improve approaches to deliver health interventions.  She has worked on  HIV, TB, malaria, diarrheal disease, pneumonia and oncology issues and across drugs, vaccines and diagnostics.

In biopharmaceuticals, her work has included re-designing decision making structures, processes and operations across R&D and Commercial organizations, creating market and competitive strategies for therapeutics, and developing R&D portfolio management strategies and processes.

Before joining BCG, Wendy worked for the Organization for Economic Cooperation and Development in Paris, where she evaluated and analyzed global trends in international trade, investment, employment, R&D and structural change across industries.  She also worked as a Senior Economist for the U.S. Bureau of Labor Statistics.  Wendy earned an AB in economics from the University of Michigan and an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.